NANJING, China, April 26, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2011 on Tuesday, May 10, 2011, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Tuesday, May 10 at 8 p.m. Beijing/Hong Kong time).
|
To access the conference call, please dial: |
||
|
United States toll-free: |
+1.800.573.4840 |
|
|
International: |
+1.617.224.4326 |
|
|
China Telecom: |
10.800.120.2655/10.800.130.0399/10.800.152.1490 |
|
|
China Netcom: |
10.800.852.1490/10.800.712.2655 |
|
|
China 400 (for mobile users) |
400.881.1630 / 400.881.1629 |
|
|
Hong Kong: |
+852.3002.1672 |
|
Please ask to be connected to Q1 2011 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 26446178.
Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.
|
Following the earnings conference call, an archive of the call will be available by dialing: |
||
|
United States toll-free: |
+1.888.286.8010 |
|
|
International: |
+1.617.801.6888 |
|
The passcode for replay participants is: 26589448.The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.
|
Investor and Media Contacts: |
|
|
Email: ir@simcere.com |
|
|
In Nanjing: |
|
|
Yehong Zhang |
|
|
President |
|
|
Simcere Pharmaceutical Group |
|
|
Tel: +86-25-8556-6666 x8811 |
|
|
In the United States: |
|
|
Kate Tellier |
|
|
Brunswick Group |
|
|
Tel: +1-212-333-3810 |
|
|
In Beijing: |
|
|
Yue Yu |
|
|
Brunswick Group |
|
|
Tel: +86-10-5960-8600 |
|
|
In Hong Kong: |
|
|
Joseph Lo Chi-Lun |
|
|
Brunswick Group |
|
|
Tel: +852-3512-5000 |
|
